Adamas Pharmaceuticals Inc

+0.05 (+0.62%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)368.25M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$24.91 Million
Adjusted EPS-$0.23
See more estimates
10-Day MA$7.66
50-Day MA$5.40
200-Day MA$5.24
See more pivots

Adamas Pharmaceuticals Inc Stock, NASDAQ:ADMS

1900 Powell Street, Suite 1000, Emeryville, California 94608
United States of America
Phone: +1.510.450.3500
Number of Employees: 138


Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinsonâ??s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.